SCHEMBL20115435

SCHEMBL20115435

CC(C)OC(=O)c1ccc(-c2ccc(/C=N/NC(=S)NN)o2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 7/20 0.80
NPC1 O15118 6/20 0.60
MAPT P10636 6/20 0.60
KDM4E B2RXH2 4/20 0.60
PKM P14618 2/20 0.60
POLB P06746 1/20 0.60
HSP90AA1 P07900 1/20 0.60
APEX1 P27695 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
RAB9A P51151 5/20 0.57
ALDH1A1 P00352 3/20 0.57
KEAP1 Q14145 1/20 0.52
NFE2L2 Q16236 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
PRMT5 O14744 1/20 0.48
WDR77 Q9BQA1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20115436 0.89 PHGDH (1.00) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL20115433 0.85 PHGDH (0.80) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL21292822 0.83 PHGDH (1.00) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL20115432 0.83 PHGDH (1.00) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL21292829 0.82 PHGDH (0.77) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL20115437 0.82 PHGDH (0.77) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL4323444 0.79 PHGDH (0.81) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL4323441 0.79 PHGDH (0.81) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL28373198 0.78 PHGDH (0.79) PHGDHNPC1MAPTKDM4EPKM
SCHEMBL28373195 0.78 PHGDH (0.79) PHGDHNPC1MAPTKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10722489-B2 D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof PEKING UNIVERSITY (CN) 2020-07-28 US disclosed
US-20200054593-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF UNIV BEIJING (CN) 2020-02-20 US disclosed
US-20190262303-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF UNIV BEIJING (CN) 2019-08-29 US disclosed
WO-2018076537-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF 北京大学 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10722489-B2 D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof MDH2, MDH1, DLD PHGDH 4/4885NPC1 4801/4885MAPT 3785/4885
US-20200054593-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF MDH2, MDH1, DLD PHGDH 4/4885NPC1 4801/4885MAPT 3785/4885
US-20190262303-A1 D-3-PHOSPHOGLYCERATE DEHYDROGENASE ALLOSTERIC INHIBITOR AND USE THEREOF MDH2, MDH1, DLD PHGDH 4/4885NPC1 4801/4885MAPT 3785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.